Peplin, Inc.
Positive Results for Peplin’s First Phase III AK Trial
Published in Drug Week, June 5th, 2009
Peplin, Inc. (ASX:PLI) announced positive results for PEP005 (ingenol mebutate) Gel in REGION-I, its Australian and US based Phase III actinic (solar) keratosis (AK) clinical trial for the treatment of lesions on non-head locations, which include the trunk and extremities. AK is a common pre-cancerous skin condition caused by sun exposure, which can develop into skin cancers if left untreated.
Peplin’s Chief Executive Officer, Tom Wiggans, is pleased with the positive results and said: “Once again, our team has done an excellent job of obtaining great clinical results while completing our first Phase III trial within the expected timeframe.”
He...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2009-06-05)
More Articles from Drug Week
- American Society for Nutrition
Vitamin D insufficiency linked to bacterial vaginosis in pregnant women - Beth Israel Deaconess Medical Center
Study indicates that a common virus could cause high blood pressure - BioMed Central
Trace elements unbalanced in dialysis patients - Cardiff University
Blood tests and better communication skills could cut over-prescribing of antibiotics - Case Western Reserve University
Researchers make discovery in colon cancer prevention - JAMA and Archives Journals
Bone marrow cell therapy may be beneficial for patients with ischemic heart disease - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
